Mersana Therapeutics (MRSN) Investor Presentation - Slideshow

Financial Position and Strategic Outlook - Mersana maintains a strong financial foundation with approximately $100 million in cash and a $15 million credit facility to fund operations into mid-2021[6] - The company is positioned for a transformational 2020, focusing on clinical proof-of-concept and advancing multiple development candidates[6][72] XMT-1536 Clinical Progress - XMT-1536 demonstrated clinical activity in heavily pretreated patients, with a 16% partial response (PR) rate in all ovarian cancer patients and a 28% PR rate in those receiving doses ≥30 mg/m²[27] - The drug candidate is well-tolerated with no Grade 4 or 5 treatment-related adverse events and no severe toxicities such as neutropenia or ocular toxicity[25] - Expansion cohorts are currently evaluating doses up to 52 mg/m², with interim data readouts scheduled for 2Q and 2H 2020[33][36][72] Pipeline and Platform Innovation - XMT-1592, a Dolasynthen ADC, showed four-fold greater activity in lung patient-derived xenograft (PDX) models compared to XMT-1536[39] - The B7-H4 DolaLock ADC program is advancing into IND-enabling studies in 2020, targeting high unmet medical needs in tumors such as triple-negative breast cancer[46][47] - Immunosynthen ADCs have demonstrated the ability to induce complete regression in multiple models with a single dose and show limited systemic cytokine induction despite extended plasma exposure[14][67] - The company plans to select its first Immunosynthen development candidate in 2020 and disclose the data package in 2H 2020[70][72]